Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.

Yasuda G, Yatsu K, Yamamoto Y, Hirawa N.

Kidney Blood Press Res. 2012;36(1):131-8. doi: 10.1159/000341491. Epub 2012 Oct 23.

2.

Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.

Mori Y, Nishikawa Y, Iizuka T, Zenimura N, Matsumoto T, Hiramatsu K, Komiya M.

Drugs R D. 2011;11(2):171-90. doi: 10.2165/11592450-000000000-00000.

3.

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.

Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.

Hypertens Res. 2002 Nov;25(6):849-55.

4.

Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.

Neutel J, Shojaee A, Maa JF.

Adv Ther. 2012 Jun;29(6):508-23. doi: 10.1007/s12325-012-0030-z. Epub 2012 Jul 4.

PMID:
22773358
5.

Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.

Wright JT Jr, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Holdbrook FK, Lukas MA, Iyengar M.

J Clin Hypertens (Greenwich). 2007 Nov;9(11):842-9.

6.

[Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].

Hanon O, Laroche P, Vidal JS, Pannier B, Postel-Vinay N, Vaisse B, Girerd X.

Ann Cardiol Angeiol (Paris). 2012 Jun;61(3):218-23. doi: 10.1016/j.ancard.2012.05.002. Epub 2012 May 23. French.

PMID:
22695025
7.

Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.

Nosadini R, Tonolo G.

J Am Soc Nephrol. 2002 Nov;13 Suppl 3:S216-23. Review.

8.
9.

Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.

Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.

Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47. Epub 2005 Oct 20.

PMID:
16487914
10.

Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.

Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Bakris GL; GEMINI Investigators..

J Cardiometab Syndr. 2008 Fall;3(4):211-7. doi: 10.1111/j.1559-4572.2008.00017.x.

11.

Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.

Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G.

J Hum Hypertens. 2012 Apr;26(4):214-9. doi: 10.1038/jhh.2011.22. Epub 2011 Mar 17.

PMID:
21412266
12.

Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K.

Clin Exp Nephrol. 2013 Feb;17(1):41-50. doi: 10.1007/s10157-012-0677-4. Epub 2012 Aug 17.

PMID:
23011292
13.
14.
15.

Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.

Ishimitsu T, Ohno E, Nakano N, Furukata S, Akashiba A, Minami J, Numabe A, Matsuoka H.

Clin Exp Hypertens. 2011;33(6):366-72. doi: 10.3109/10641963.2010.503299. Epub 2011 Jul 28.

PMID:
21797795
16.

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.

Huang RS, Cheng YM, Zeng XX, Kim S, Fu P.

Chin Med J (Engl). 2016 Mar 5;129(5):562-9. doi: 10.4103/0366-6999.176987.

17.

Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.

Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.

Hypertens Res. 2007 Jun;30(6):529-33.

PMID:
17664856
18.

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F.

Ann Intern Med. 1997 Jun 15;126(12):955-9.

PMID:
9182472
19.
20.

Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.

Ehmer B, van der Does R, Rudorf J.

Drugs. 1988;36 Suppl 6:136-40.

PMID:
2908300

Supplemental Content

Support Center